Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
38
CTMX Quote, Financials, Valuation and Earnings
Last price:
$1.08
Seasonality move
:
-0.08%
Day range:
$1.05 - $1.11
52-week range:
$0.83 - $5.85
Dividend yield:
0%
P/E ratio:
6.41x
P/S ratio:
0.72x
P/B ratio:
--
Volume:
1.3M
Avg. volume:
1.5M
1-year change:
-24.31%
Market cap:
$85.3M
Revenue:
$101.2M
EPS (TTM):
$0.17
Analysts' Opinion
-
Consensus RatingCytomX Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, CytomX Therapeutics has an estimated upside of 384.95% from its current price of $1.09.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.09.
Fair Value
-
According to the consensus of 0 analysts, CytomX Therapeutics has 384.95% upside to fair value with a price target of -- per share.
CTMX vs. S&P 500
-
Over the past 5 trading days, CytomX Therapeutics has underperformed the S&P 500 by -6.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CytomX Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CytomX Therapeutics has grown year-over-year revenues for 7 quarters straight. In the most recent quarter CytomX Therapeutics reported revenues of $33.4M.
Earnings Growth
-
CytomX Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CytomX Therapeutics reported earnings per share of $0.07.
Enterprise value:
-32.3M
EV / Invested capital:
1.38x
Price / LTM sales:
0.72x
EV / EBIT:
-4.81x
EV / Revenue:
-0.26x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-3.78x
Gross Profit (TTM):
--
Return On Assets:
7.63%
Net Income Margin (TTM):
10.92%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
12.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $20.5M | $94.7M | $126.6M | $26.4M | $33.4M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$150.4M | -$15.4M | $6.7M | $3.1M | $4.1M | |
| EBITDA | -$147.9M | -$13.1M | $8.6M | $3.6M | $4.5M | |
| Diluted EPS | -$2.29 | -$0.16 | $0.17 | $0.04 | $0.07 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $340.3M | $241M | $200.3M | $201.2M | $124.2M | |
| Total Assets | $375.2M | $371.2M | $226.5M | $221.2M | $139M | |
| Current Liabilities | $102M | $99.8M | $97.8M | $146.8M | $119.2M | |
| Total Liabilities | $327.1M | $259.6M | $198M | $272.4M | $162.4M | |
| Total Equity | $48.1M | $111.7M | $28.5M | -$51.2M | -$23.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$140.6M | -$35.5M | -$88.3M | -$18.2M | -$20.7M | |
| Cash From Investing | -$1.8M | -$63.7M | $97.4M | -$42.9M | $18.2M | |
| Cash From Financing | $1.1M | $30.2M | $5.5M | $29.7M | -- | |
| Free Cash Flow | -$142.4M | -$36.2M | -$88.8M | -$18.3M | -$20.7M | |
CTMX
Sector
Market Cap
$85.3M
$45.6M
Price % of 52-Week High
18.63%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-24.31%
-31.35%
Beta (5-Year)
1.069
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.11
200-day SMA
Sell
Level
$1.51
Bollinger Bands (100)
Sell
Level
1.03 - 1.23
Chaikin Money Flow
Sell
Level
-4.1M
20-day SMA
Sell
Level
$1.13
Relative Strength Index (RSI14)
Sell
Level
49.29
ADX Line
Buy
Level
19.93
Williams %R
Neutral
Level
-78.5714
50-day SMA
Buy
Level
$1.06
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
235.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.2118)
Sell
CA Score
(Annual)
Level (-4.0375)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (96.0136)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Stock Forecast FAQ
In the current month, CTMX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CTMX average analyst price target in the past 3 months is --.
-
Where Will CytomX Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that CytomX Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About CytomX Therapeutics?
Analysts are divided on their view about CytomX Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CytomX Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is CytomX Therapeutics's Price Target?
The price target for CytomX Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CTMX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CytomX Therapeutics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CTMX?
You can purchase shares of CytomX Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CytomX Therapeutics shares.
-
What Is The CytomX Therapeutics Share Price Today?
CytomX Therapeutics was last trading at $1.08 per share. This represents the most recent stock quote for CytomX Therapeutics. Yesterday, CytomX Therapeutics closed at $1.09 per share.
-
How To Buy CytomX Therapeutics Stock Online?
In order to purchase CytomX Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 19.35% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.91% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
